NCT05441150 is a Phase 4 clinical trial of Low dose ketamine infusion in Liver Failure, sponsored by Inonu University.

Who is sponsoring NCT05441150?

NCT05441150 is sponsored by Inonu University.

What drugs are being tested in NCT05441150?

Interventions in NCT05441150: Low dose ketamine infusion, 0.9% NaCl infusion.

What condition does NCT05441150 study?

NCT05441150 studies Liver Failure, Liver Transplant; Complications, Post Operative Pain.

Is NCT05441150 still recruiting?

NCT05441150 is currently status unknown. Last updated 5 July 2022.

Last reviewed 2022-07-05 · How we verify

NCT05441150

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Ketamine Infusion on Postoperative Analgesia of Living Liver Donors

Status unknown Phase 4 Last updated 5 July 2022

What this trial tests

Phase 4 trial testing Low dose ketamine infusion in Liver Failure in 2 participants. Status unknown.

Timeline

1 June 2022

Primary endpoint
1 October 2022

1 November 2022

Quick facts

Lead sponsor	Inonu University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	2
Start date	1 June 2022
Primary completion	1 October 2022
Estimated completion	1 November 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Low dose ketamine infusion — full drug profile →
0.9% NaCl infusion — full drug profile →

Conditions studied

Liver Failure — all drugs for Liver Failure →
Liver Transplant; Complications — all drugs for Liver Transplant; Complications →
Post Operative Pain — all drugs for Post Operative Pain →

Sponsor

Inonu University

Who can join

Adults 18 to 65, any sex, with Liver Failure or Liver Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Because of the insufficiency of cadaveric organs and increasing need for organs, the interest in living donor liver transplantation have been greatly increased. The relative reduction of the remaining liver after the operation in Living Liver Donors makes it difficult and compelling to choose a very effective and very safe method in the management of postoperative analgesia. Opioids are the main agents used in the postoperative analgesia of Live Liver Donors. Opioids have serious side effects such as respiratory depression, apnea, circulatory collapse, coma, and death. Both short-term and long-term administration of opioids cause acute opioid-induced hyperalgesia. Ketamine, an NMDA receptor antagonist, has been hypothesized to counter opioid tolerance and NMDA receptor-mediated central sensitization. Various studies and systematic reviews have shown that low-dose ketamine has an opioid-sparing effect in all surgical patients. Although low-dose ketamine has been shown to be beneficial overall in relieving pain, it is unclear whether it has an identified benefit in hepatectomy cases. The aim of this clinical trial was to evaluate the effect of low-dose ketamine administration on postoperative analgesia in living donor liver donors undergoing right hepatectomy procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Failure

Currently open trials in the same condition.

NCT07312864 — Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome · Phase 1, PHASE2 · recruiting
NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting
NCT06908746 — Efficacy and Safety of Citrate Anticoagulation in CRRT for Patients With Liver Failure/DysfuncTION, the CAUTION Trial! A · recruiting
NCT06224023 — Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure · recruiting

Other Inonu University trials

Trials by the same sponsor.

NCT06553807 — Genital Self İmage and Satisfaction With Genital Appearance · NA · not yet recruiting
NCT07480122 — Motor Imaging, Neglect, and Upper Extremity Function in Stroke · not yet recruiting
NCT07463326 — The Efficacy of Transcutaneous Tibial Nerve Stimulation in Women With Idiopathic Overactive Bladder · NA · enrolling by invitation
NCT07510737 — The Effect of Cross Training on Clinical and Functional Outcomes in Frozen Shoulder Rehabilitation · not yet recruiting
NCT07530211 — The Effect of Systemic Factors on Peri-implant Health Status and Clinical Indices · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05441150 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inonu University
Last refreshed: 5 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05441150.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing